H David Inzunza
Overview
Explore the profile of H David Inzunza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phillips T, Millett M, Zhang X, Jansson M, Cleveland R, Simmons P, et al.
Appl Immunohistochem Mol Morphol
. 2017 Dec;
26(1):6-12.
PMID: 29189265
Nivolumab is a monoclonal antibody that blocks the interaction between programmed cell death 1 (PD1) and programmed cell death 1-ligand 1 (PD-L1), resulting in enhanced antitumor activity by the immune...
2.
Cogswell J, Inzunza H, Wu Q, Feder J, Mintier G, Novotny J, et al.
Mol Diagn Ther
. 2016 Sep;
21(1):85-93.
PMID: 27667773
Aim: Nivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab...
3.
Gibney G, Kudchadkar R, DeConti R, Thebeau M, Czupryn M, Tetteh L, et al.
Clin Cancer Res
. 2014 Dec;
21(4):712-20.
PMID: 25524312
Purpose: The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected stage IIIC and IV...
4.
Weber J, Kudchadkar R, Yu B, Gallenstein D, Horak C, Inzunza H, et al.
J Clin Oncol
. 2013 Oct;
31(34):4311-8.
PMID: 24145345
Purpose: Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlative biomarkers were assessed with or...
5.
Rankin C, Veri M, Gorlatov S, Tuaillon N, Burke S, Huang L, et al.
Blood
. 2006 Jun;
108(7):2384-91.
PMID: 16757681
Human CD32B (FcgammaRIIB), the low-affinity inhibitory receptor for IgG, is the predominant Fc receptor (FcR) present on B cells. Immunohistochemical and expression studies have identified CD32B expression in a variety...